Banks Benefit From ...
Health Care: Drugs
CEL-SCI Corporation (CVM: AMEX)
$0.42 0.04 | 10.38%
02/09/12 - 03:58 PM ET
4.02M / 670.20K
Vol / Avg. Vol:0.40 / 0.38
Open / Prev. Close:0.38 - 0.44
Today's Range:0.27 - 0.76
52 Wk Range:37.98%
Performance YTD:TheStreet Rating:
Portfolios with CVM
- Portfolio NameUser Type
- Userherb's portfolio
- UserBlue OAK
- Usercgimene Portfolio 1
- Userjjkohls Portfolio 1
- UserRet2009
- UserJLR
- Userrschurchill Portfolio 1
- Usermoney4me Portfolio 1
- UserJLR 1
- Usergiving me stock
Latest CVM Headlines from TheStreet
- Biotech Data Mining Comes Up Empty 06.29.11 | 07:06 am
- Cel-Sci Settles Over South African Partner Flap 05.17.11 | 09:05 am
- Cel-Sci: The Multikine Sweet 16 05.03.11 | 12:05 pm
- Sweet Spot in Biotech Investing 04.13.11 | 12:04 pm
- Biotech Stock Mailbag: Exact Sciences 02.25.11 | 07:02 am
- Biotech Stock Mailbag: Orexigen Therapeutics 01.28.11 | 07:01 am
- Biotech Stock Mailbag: Vivus 09.24.10 | 07:09 am
- Biotech Stock Mailbag: Alkermes 08.06.10 | 07:08 am
- New Cancer Vaccine the Next Dendreon? 05.03.10 | 01:05 pm
- Biotech Stock Mailbag: Sequenom 03.12.10 | 07:03 am
Press Releases for CVM
- CEL-SCI Corporation Reports First Quarter 2012 Financial Results - Business Wire 02.09.12 | 04:02 pm
- CEL-SCI Corporation To Raise $5.76 Million In Registered Direct Offering - Business Wire 01.26.12 | 09:01 am
- CEL-SCI Corporation Releases Letter To Shareholders - Business Wire 01.20.12 | 04:01 pm
- CEL- SCI Corporation Authorizes Expansion Of Phase III Clinical Trial To An Additional 4 European Countries - Business Wire 12.27.11 | 08:12 am
- CEL-SCI Corporation Announces Fiscal 2011 Financial Results - Business Wire 12.23.11 | 04:12 pm
- CEL- SCI Corporation Updates Phase III Clinical Activities For Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection) - Business Wire 12.07.11 | 09:12 am
- CEL- SCI Corporation Updates Phase III Clinical Activities For Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection) - Business Wire 11.02.11 | 08:11 am
- CEL-SCI Corporation Announces The Closing Of Its $4 Million Registered Direct Offering Of Common Stock And Warrants - Business Wire 10.07.11 | 09:10 am
- CEL-SCI Corporation To Raise $4 Million In Registered Direct Offering - Business Wire 10.04.11 | 09:10 am
- CEL-SCI’s Taiwanese Partner Orient Europharma Presents Development Strategies In Taiwan For Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection) At World Orphan Drug Conference Today In Seoul, Korea - Business Wire 09.15.11 | 09:09 am
Partner Headlines for CVM
- 2 Biotechs On Teva's Radar Screen - Seeking Alpha 02.06.12 | 08:02 am
- Biopharma Stocks To Watch This Week - Seeking Alpha 01.19.12 | 09:01 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- CEL- SCI Corporation Updates Positive Phase III Clinical Activities for Investigational Cancer Therapy Multikine - Benzinga 12.07.11 | 09:12 am
- Institutional 5% Ownership Filings Last Week By The World's Leading Funds - Seeking Alpha 10.18.11 | 09:10 am
- Top Picks From Tuesday's Big News Movers - Seeking Alpha 10.05.11 | 08:10 am
- SuperGen Acquiring Cel-Sci Would Be A Win-Win - Seeking Alpha 08.31.11 | 09:08 am
- CEL-SCI Corporation Receives Government Approval in Poland to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer - Benzinga 05.04.11 | 09:05 am
- CEL-SCI Corporation Receives Russian Government Approval to Commence Phase III Clinical Trial - Benzinga 01.05.11 | 09:01 am
- Healthcare Headlines: Santarus Rallies, Amgen Announces Results - Seeking Alpha 10.06.10 | 08:10 am
